Summary
Postural instability and gait disorders (PIGD) are the primary causes of disability in many but not all advanced Parkinson's disease (PD) patients. We have measured the concentrations of serotonin, 5-hydroxytryptophan (5-HTP), 5-hydroxy-3-indoleacetic acid (5-HIAA), and homovanillic acid (HVA) in samples of ventricular cerebrospinal fluid from ten PD patients with severe disability from PIGD and from ten PD patients with tremor and levodopa induced dyskinesia as their predominant motor dysfunction. The two groups were prospectively matched for duration of disease and age. No significant differences between the two groups were found in the concentration (mean ± SD in ng/ml, PIGD dominant vs. tremordyskinesia dominant) of 5-HIAA (106 ± 50 vs. 99 ± 34) or HVA (1,068 ± 595 vs. 881 ± 469). Serotonin concentration was significantly lower (0.7 ± 0.5 vs. 1.5 ± 0.9) and 5-HTP concentration was substantially higher (684 ± 1,054 vs. 6 ± 5) in the patient group with PIGD as their predominant symptoms. Thus, the distinguishing feature of patients with severe PIGD appears to be a derangement in indoleamine metabolism at the reaction step catalyzed by aromatic amino acid decarboxylase (AADC). These findings suggest that aggravation of PIGD in advanced Parkinson's may be related in part to impaired serotonergic transmission secondary to inhibition or down regulation of AADC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alburges ME, Narang N, Wamsley JK (1993) A sensitive and rapid HPLC-ECD method for the simultaneous analysis of norepinephrine, dopamine, serotonin and their primary metabolites in brain tissue. Biomed Chromatogr 7: 306–310
Bloem BR (1992) Postural instability in Parkinson's disease. Clin Neurol Neurosurg 94: S41–45
Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 37: 1539–1542
Chase TN, Ng LK (1972) Central monoamine metabolism in Parkinson's disease. Arch Neurol 27: 486–491
Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54: 691–699
D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH (1987) Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22: 229–236
Furukawa Y, Kondo T, Nishi K, Yokochi F, Narabayashi H (1991) Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: a comparison between akineto-rigid and tremor types. J Neurol Sci 103: 232–237
Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990a) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 510: 104–107
Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB (1990b) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27: 373–385
Hashiguti H, Nakahara D, Maruyama W, Naoi M, Ikeda T (1993) Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Transm [Gen Sect] 93: 213–223
Iacono RP, Shima F, Lonser RR, Kuniyoshi S, Maeda G, Yamada S (1995) The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease [see comments]. Neurosurgery 36: 1118–11125 (discussion 1125–1127)
Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T (1994) Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm [Park Dis Dement Sect] 8: 149–158
Indo T, Takahashi A (1986) An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years — when should L-dopa therapy be initiated? Jpn J Med 25: 114–121
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al (1990) Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40: 1529–1534
Jellinger KA, Paulus W (1992) Clinico-pathological correlations in Parkinson's disease. Clin Neurol Neurosurg 94: S86-S88
Klawans HL (1986) Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord 1: 187–192
Koller WC, Glatt S, Vetere-Overfield B, Hassanein R (1989) Falls and Parkinson's disease. Clin Neuropharmacol 12: 98–105
Koskiniemi M, Laakso J, Kuurne T, Laipio M, Harkonen M (1985) Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L-tryptophan administration. Acta Neurol Scand 71: 127–132
Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A (1996) Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy, Adv Neurol 69: 545–550
Narabayashi H, Yokochi F, Ogawa T, Igakura T (1991) Analysis of L-threo-3,4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No To Shinkei 43: 263–268
Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743–755
Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321–28
Scatton B, Dennis T, L'Heureux R, Monfort JC, Duyckaerts C, Javoy-Agid F (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Res 380: 181–185
Sjostrom R, Ekstedt J, Anggard E (1975) Concentration gradients of monoamine metabolites in human cerebrospinal fluid. J Neurol Neurosurg Psychiatry 38: 666–668
Sourkes TL, Young SN, Garelis E, Lal S (1975) Gradients of concentrations of tryptophan and 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF). Acta Vitaminol Enzymol 29: 97–99
Strittmatter MM, Cramer H (1992) Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport 3: 413–416
Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H (1993) Concentrations of serotonin and its related substances in the cereborspinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 150: 71–74
Trouvin JH, Maubrey MC, Raynal H, Jacquot C (1991) Effect of L-dopa loading on 5-HTP decarboxylation in rat brain areas. Fundam Clin Pharmacol 5: 497–502
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iacono, R.P., Kuniyoshi, S.M., Ahlman, J.R. et al. Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. J. Neural Transmission 104, 451–459 (1997). https://doi.org/10.1007/BF01277663
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01277663